News >

Expert Discusses Immunotherapy Across Gynecologic Malignancies

Danielle Bucco
Published: Monday, Oct 23, 2017

Dmitriy Zamarin, MD, PhD

Dmitriy Zamarin, MD, PhD
Immunotherapy is slowly evolving in the gynecologic malignancies landscape and has moved beyond only having a role in ovarian cancer, according to Dmitriy Zamarin, MD, PhD.

on Treatment of Ovarian Cancer, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the role of immunotherapy for patients with gynecologic malignancies.

OncLive: Beyond ovarian cancer, in what other gynecologic malignancies has immunotherapy shown potential?

Zamarin: Ovarian cancer is not the only cancer that we treat with immunotherapy. Immunotherapy has also been shown to be effective in endometrial cancer. We already have a very effective drug, pembrolizumab, approved for MSI-H endometrial cancers or for any MSI-H tumor. It could encompass some of the patients with ovarian cancer, but it is specific to the endometrial histology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x